AR061273A1 - THERAPY USING CITOCINE INHIBITORS - Google Patents

THERAPY USING CITOCINE INHIBITORS

Info

Publication number
AR061273A1
AR061273A1 ARP070102483A ARP070102483A AR061273A1 AR 061273 A1 AR061273 A1 AR 061273A1 AR P070102483 A ARP070102483 A AR P070102483A AR P070102483 A ARP070102483 A AR P070102483A AR 061273 A1 AR061273 A1 AR 061273A1
Authority
AR
Argentina
Prior art keywords
attached
forming
target protein
orientation
variables
Prior art date
Application number
ARP070102483A
Other languages
Spanish (es)
Inventor
Constance A Crowley
Bernard King
Bonnie Hepburn
Nancy G J Delaet
Stephen Miller
Carrie Gail Grove
Christopher J Larson
Kent Pryor
Lewis J Shuster
Justin Ernst
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of AR061273A1 publication Critical patent/AR061273A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Métodos para tratar, prevenir, modificar y manejar las enfermedades mediadas con citocina o las enfermedades relacionadas, que comprenden la administracion de un compuesto, tal como un inhibidor de citocina, solo o en combinacion con terapéuticos conocidos. Composiciones farmacéuticas y regímenes de dosis usando los compuestos descritos. Uso de compuestos como se describen en este documento, opcionalmente en conjuncion con otras terapias, para el tratamiento de enfermedades autoinmunes, enfermedades inflamatorias, enfermedades cardiovasculares y cáncer. Reivindicacion 1: Un método para tratar un trastorno mediado por una o más citocinas, caracterizado porque comprende administrar a un sujeto en necesidad de tal tratamiento una cantidad terapéuticamente efectiva de un compuesto, en donde el compuesto se selecciona de: a) G-N(H)X-Ar-L-Q en donde las variables G, X, Ar, L, y Q son como se definieron en las Listas II, III o IV; b) G-X-N(H)Ar-L-Q en donde las variables G, X, Ar, L, y Q son como se definieron en las Listas V, VI, o VII; c) G-anillo-Ar-L-Q, en donde las variables G, anillo, Ar, L, y Q son como se definieron en la Lista VIII; d) formula (2) en donde las variables G, X', Ar, L, y Q son como se definieron en la Lista IX, e) formula (3) en donde las variables G, L1, L2, L3, A, Ar, y Q son como se definieron en la Lista X; f) formula (4) en donde las variables G, X, Y, L1, L2, A, B, D, E y Q son como se definieron en la Lista XI, g) un compuesto que comprende: una porcion de direccion, TM que comprende por lo menos un grupo amida que tiene un NH amida, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo, y en donde la porcion de direccion no es un grupo urea; una porcion de expansion de cavidad, PEM unida directamente a la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, la porcion no plana forma interacciones hidrofobicas con la proteína objetivo; y una porcion de orientacion, OM que comprende una porcion hidrofobica plana y unida a un átomo diferente de la porcion de direccion que la porcion de expansion de cavidad, la porcion de orientacion capaz de formar una interaccion aromática p-p o borde a cara con la proteína objetivo; h) un compuesto que comprende una porcion de direccion, TM, que comprende un grupo amida que tiene un NH amida y carbonilo, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo; una porcion de expansion de cavidad, PEM, unida directamente a la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, en donde la porcion no plana es capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion de orientacion, OM, que comprende un anillo piridilo y unida a un átomo diferente de la porcion de direccion que la porcion de expansion de cavidad, en donde la porcion de orientacion es capaz de formar interacciones hidrofobicas con la proteína objetivo; y una porcion de anclaje, AM, unida indirectamente a la porcion de orientacion por una porcion conectora, L, en donde la porcion de anclaje es capaz de formar por lo menos una interaccion de enlace de hidrogeno con una cavidad de union a ATP de la proteína objetivo; i) un compuesto que comprende: una porcion de direccion, TM, que comprende un NH amida y carbonilo, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo; una porcion de expansion de cavidad, PEM, unida directamente al carbonilo de la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, en donde la porcion no plana capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion de orientacion, OM, que comprende un anillo arilo o heteroarilo de 6 miembros y unida al NH de la porcion de direccion, en donde la porcion de orientacion es capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion conectora, L, unida a un átomo diferente de la porcion de orientacion que la porcion de direccion, en donde la porcion conectora comprende una porcion heteroarilo de 5 miembros y el punto de union en la porcion heteroarilo es un átomo de carbono; y una porcion de anclaje, AM, unida a la porcion de orientacion por la porcion conectora, L, en donde la porcion de anclaje es capaz de formar por lo menos una interaccion de enlace de hidrogeno con una cavidad de union a ATP de la proteína objetivo; o un estereoisomero, tautomero, solvato, profármaco, o sales farmacéuticamente aceptable de cualquiera de uno o más de (a)-(i).Methods for treating, preventing, modifying and managing cytokine-mediated diseases or related diseases, which comprise the administration of a compound, such as a cytokine inhibitor, alone or in combination with known therapeutics. Pharmaceutical compositions and dose regimens using the compounds described. Use of compounds as described herein, optionally in conjunction with other therapies, for the treatment of autoimmune diseases, inflammatory diseases, cardiovascular diseases and cancer. Claim 1: A method of treating a disorder mediated by one or more cytokines, characterized in that it comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound, wherein the compound is selected from: a) GN (H) X-Ar-LQ where the variables G, X, Ar, L, and Q are as defined in Lists II, III or IV; b) G-X-N (H) Ar-L-Q where the variables G, X, Ar, L, and Q are as defined in Lists V, VI, or VII; c) G-ring-Ar-L-Q, where the variables G, ring, Ar, L, and Q are as defined in List VIII; d) formula (2) where the variables G, X ', Ar, L, and Q are as defined in List IX, e) formula (3) where the variables G, L1, L2, L3, A, Ar, and Q are as defined in List X; f) formula (4) wherein the variables G, X, Y, L1, L2, A, B, D, E and Q are as defined in List XI, g) a compound comprising: a direction portion, TM comprising at least one amide group having an NH amide, the address portion capable of forming one or more hydrogen bonds with a target protein, and wherein the address portion is not a urea group; a cavity expansion portion, PEM attached directly to the direction portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, the non-plane portion forms hydrophobic interactions with the target protein; and an orientation portion, OM comprising a flat hydrophobic portion and attached to an atom different from the direction portion than the cavity expansion portion, the orientation portion capable of forming a pp or edge-to-face aromatic interaction with the protein objective; h) a compound comprising a direction portion, TM, comprising an amide group having an NH amide and carbonyl, the direction portion capable of forming one or more hydrogen bonds with a target protein; a cavity expansion portion, PEM, directly attached to the direction portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, wherein the non-plane portion is capable of forming hydrophobic interactions with the target protein; an orientation portion, OM, comprising a pyridyl ring and attached to an atom different from the direction portion than the cavity expansion portion, wherein the orientation portion is capable of forming hydrophobic interactions with the target protein; and an anchor portion, AM, indirectly attached to the orientation portion by a connector portion, L, wherein the anchor portion is capable of forming at least one hydrogen bonding interaction with an ATP binding cavity of the target protein; i) a compound comprising: a direction portion, TM, comprising an NH amide and carbonyl, the direction portion capable of forming one or more hydrogen bonds with a target protein; a cavity expansion portion, PEM, directly attached to the carbonyl of the steering portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, wherein the non-flat portion capable of forming hydrophobic interactions with the target protein; an orientation portion, OM, comprising a 6-membered aryl or heteroaryl ring and attached to the NH of the address portion, wherein the orientation portion is capable of forming hydrophobic interactions with the target protein; a connecting portion, L, attached to an atom different from the orientation portion than the steering portion, wherein the connecting portion comprises a 5-membered heteroaryl portion and the point of attachment in the heteroaryl portion is a carbon atom; and an anchor portion, AM, attached to the orientation portion by the connector portion, L, wherein the anchor portion is capable of forming at least one hydrogen bonding interaction with an ATP binding cavity of the protein objective; or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salts of any one or more of (a) - (i).

ARP070102483A 2006-06-09 2007-06-08 THERAPY USING CITOCINE INHIBITORS AR061273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US83307806P 2006-07-24 2006-07-24
US83527006P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
AR061273A1 true AR061273A1 (en) 2008-08-13

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102483A AR061273A1 (en) 2006-06-09 2007-06-08 THERAPY USING CITOCINE INHIBITORS

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101426093B1 (en) 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CL2007002866A1 (en) 2006-10-04 2008-07-04 Pharmacopeia Inc COMPOUNDS DERIVED FROM 6-SUBSTITUTES-2- (BENCIMIDAZOLIL) PURINA AND PURINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASE, DISEASE MEDIATED BY M
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
LT2170396T (en) 2007-08-03 2017-03-10 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US20110230497A1 (en) * 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
CA2764387A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
WO2011063076A1 (en) * 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EA026094B1 (en) * 2009-12-23 2017-03-31 Рациофарм Гмбх Solid dosage form of ticagrelor
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP6155187B2 (en) * 2010-03-30 2017-06-28 ヴァーセオン コーポレイション Polysubstituted aromatic compounds as inhibitors of thrombin
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (en) 2011-10-21 2014-11-28 Эббви Инк. COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
CN108354933A (en) 2013-03-15 2018-08-03 维颂公司 The pharmaceutical applications of polysubstituted aromatic compounds as serpin
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
PL3925607T3 (en) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
AU2015360416A1 (en) 2014-12-10 2017-06-08 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
LT3261639T (en) 2015-02-27 2022-11-25 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
CN107921046B (en) * 2015-06-12 2022-10-14 格林威治大学 Triazine derivatives as interferon-gamma inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (en) 2015-11-19 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3390396B1 (en) 2015-12-15 2022-07-06 Astrazeneca AB Isoindole compounds
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
RU2018132559A (en) 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи BINDING MOLECULES FOR MAX AS MYC MODULATORS AND THEIR APPLICATIONS
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CN115105601A (en) * 2016-06-08 2022-09-27 投资支持有限公司 Pharmaceutical combination for the treatment of cancer
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
EP3558997B1 (en) 2016-12-20 2021-01-27 AstraZeneca AB Amino-triazolopyridine compounds and their use in treating cancer
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221216T1 (en) 2016-12-22 2022-12-23 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2934230T3 (en) 2016-12-22 2023-02-20 Incyte Corp Benzooxazole derivatives as immunomodulators
CA3063729A1 (en) * 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Analgesic compounds
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN111646986B (en) * 2017-09-13 2022-03-25 厦门稀土材料研究所 Nicotinic acid derivative and preparation method and application thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
CN112020500A (en) 2017-12-22 2020-12-01 拉文纳制药公司 Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase
FI3774791T3 (en) 2018-03-30 2023-03-21 Incyte Corp Heterocyclic compounds as immunomodulators
CN112752756A (en) 2018-05-11 2021-05-04 因赛特公司 Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202115059A (en) 2019-08-09 2021-04-16 美商英塞特公司 Salts of a pd-1/pd-l1 inhibitor
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CA3159766A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
TW202128675A (en) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 Substituted tetrahydrofurans as modulators of sodium channels
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392661A1 (en) * 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
AU2004270733B2 (en) * 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
PE20080935A1 (en) 2008-08-02
TW200814998A (en) 2008-04-01
CL2007001670A1 (en) 2008-01-18
EP2035005A2 (en) 2009-03-18
WO2007146712A2 (en) 2007-12-21
AU2007257959A1 (en) 2007-12-21
CA2691214A1 (en) 2007-12-21
WO2007146712A3 (en) 2008-11-27
EP2035005A4 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
AR061273A1 (en) THERAPY USING CITOCINE INHIBITORS
JP2009506048A5 (en) Condensed imidazolo derivatives for inhibition of aldosterone synthase and aromatase
MX2021015605A (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors.
AR061101A1 (en) FENIL-TRIAZOLIL- METOXI-ARILO COMPOSITE, ITS USE FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION
AR104388A1 (en) INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
CR20220456A (en) Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
MY145465A (en) Diaminopyrimidines as p2x3 and p2x2/3 antagonists.
EA201101672A1 (en) SUBSTITUTED DERIVATIVES OF AMINOISAL ACID AS NEPRILISIN INHIBITORS
EA201290237A1 (en) KINASE INHIBITORS
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
RU2009117642A (en) APPLICATION OF SPYROXYNDOLIC COMPOUNDS AS A THERAPEUTIC MEDICINES
AR120896A1 (en) PYRIDAZINIL-THIAZOLCARBOXAMIDE COMPOUNDS AS DGKz INHIBITORS
AR115985A1 (en) PIRAZINE COMPOUNDS AND USES OF THEM
AR065092A1 (en) COMBINATION THERAPY WITH ANGIOGENESIS INHIBITORS
BRPI0509359A (en) pyridyl substituted porphyrin compounds and methods of using these
RU2009110442A (en) CONDENSED IMIDAZOLE DERIVATIVES FOR TREATMENT OF DISORDERS MEDIATED BY ALDOSTEROSYNTHASE AND / OR 11-BETA-HYDROXYLASE, AND / OR AROMATASE
PE20210176A1 (en) ARGINASE INHIBITORS AND THEIR METHODS OF USE
AR074072A1 (en) COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
RU2020131012A (en) 7-SUBSTITUTED SULFONIMIDOILPURINONE COMPOUNDS AND THEIR DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCER
Govdi et al. Betulonic acid–peptide conjugates: Synthesis and evaluation of anti-inflammatory activity
Middlemiss et al. A medicinal chemistry case study: an account of an angiotensin II antagonist drug discovery programme
JP2019503356A5 (en)
RU2013145869A (en) COMBINATION OF ANTI-CLASTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR TREATMENT OF PROSTATE CANCER
AR050043A1 (en) METHODS TO IMPROVE BIODISPONIBILITY AND PHARMACEUTICAL COMPOSITION FOR CARDIOVASCULAR DISORDERS
JP2017529386A5 (en)

Legal Events

Date Code Title Description
FB Suspension of granting procedure